Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis

Liver International

Volumn 26, Issue 10, 2006, Pages 1209-1216

  Suzuki, Ayako ^a,b   Lymp, James ^c   Sauver, Jenny St ^d   Angulo, Paul ^b   Lindor, Keith ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d Mayo Clinic   (United States)

Author keywords

Aminotransferases; Fatty liver; Hepatic inflammation; Non alcoholic

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING TEST; VALIDATION STUDY;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FATTY LIVER; FEMALE; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; URSODEOXYCHOLIC ACID;

EID: 33751009361     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01362.x     Document Type: Article

References (17)

1. Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
2. Kim W R, Poterucha J J, Porayko M K, Dickson E R, Steers J L, Wiesner R H. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 1802-5.
3. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplant 2001; 7: 608-14.
4. Kodali V P, Gordon S C, Silverman A L, McCray D G. Cryptogenic liver disease in the United States: Further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol 1994; 89: 1836-9.
5. Saunders J B, Walters J R, Davies A P, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed) 1981; 282: 263-6.
6. Regev A, Berho M, Jeffers L J, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
7. Merriman R, Ferrell L, Patti M, Ostroff J. Histological correlation of paired right lobe and left lobe liver biopsies in morbidly obese individuals with suspected non-alcoholic fatty liver disease. Hepatology 2003; 38: 158A.
8. Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54.
9. Vickers A J, Altman D G. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001; 323: 1123-4.
10. Lindor K D, Kowdley K V, Heathcote E J, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial [see comment]. Hepatology 2004; 39: 770-8.
11. Brunt E M. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
12. Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
13. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. Annu Rev Public Health 2002; 23: 151-69.
14. Bland J M, Altman D G. Some examples of regression towards the mean. BMJ 1994; 309: 780.
15. Bland J M, Altman D G. Regression towards the mean. BMJ 1994; 308: 1499.
16. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255-9.
17. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25: 779-86.